Pacira BioSciences Management
Management criteria checks 2/4
Pacira BioSciences' CEO is Frank Lee, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.018% of the company’s shares, worth $156.87K. The average tenure of the management team and the board of directors is 2.6 years and 5.3 years respectively.
Key information
Frank Lee
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | 2.6yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Nov 25Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14CEO
Frank Lee (56 yo)
less than a year
Tenure
Mr. Frank D. Lee served as an Independent Director at Bolt Biotherapeutics, Inc. since November 2021 until September 2024. He is Independent Director of Bausch Health Companies Inc. from May 14, 2024. He i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Operating Officer | 2.6yrs | US$1.53m | 0.025% $ 223.0k | |
| Chief Administrative Officer & Secretary | 10.2yrs | US$1.60m | 0% $ 0 | |
| Advisor | less than a year | US$6.88m | 0.51% $ 4.5m | |
| Executive Officer | less than a year | US$1.43m | 0.059% $ 520.5k | |
| Chief Medical Officer | 3.4yrs | US$1.59m | 0.028% $ 246.3k | |
| CEO & Director | less than a year | no data | 0.018% $ 156.9k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Principal Accounting Officer & Senior VP of Finance | 12.8yrs | US$288.82k | 0.0046% $ 40.6k | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Legal & Compliance Officer | 3yrs | US$2.05m | 0.028% $ 244.4k | |
| Vice President of Human Resources | 9.4yrs | no data | no data | |
| Chief Manufacturing Officer | 1.7yrs | no data | no data |
2.6yrs
Average Tenure
54yo
Average Age
Experienced Management: PCRX's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.018% $ 156.9k | |
| Independent Director | 13.5yrs | US$364.01k | 0.027% $ 233.9k | |
| Chairman of the Board | 13.5yrs | US$390.51k | 0.016% $ 142.2k | |
| Independent Director | 18yrs | no data | no data | |
| Independent Director | 11.5yrs | US$373.01k | 0.043% $ 373.3k | |
| Independent Director | 5.3yrs | US$325.01k | 0.011% $ 99.8k | |
| Independent Director | 1.2yrs | US$427.86k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$426.45k | 0.011% $ 93.2k | |
| Independent Director | 1.2yrs | US$427.16k | 0% $ 0 | |
| Independent Director | 7.5yrs | US$349.01k | 0.020% $ 175.4k | |
| Independent Director | 1.2yrs | US$427.16k | 0.0043% $ 37.9k |
5.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: PCRX's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 22:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pacira BioSciences, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Balaji Prasad | Barclays |
| Anita Dushyanth | Berenberg |